Medscience
Overview
The Middle Eastern and African pharmaceutical markets are highly attractive with a total population of over 570 million and annual expenditures of $31 billion on branded and generic drugs in 2021, growing at a CAGR of 6.2 percent.
However, successfully launching a new product across the region requires local infrastructure, expertise, and a deep knowledge of the complexities of these markets. This is where we come in.
We have mastered the complexities of operating in the different jurisdictions, languages, and cultures in the region; and we use our knowledge to maximize the potential for the commercial success of our partners’ products locally as well as regionally.
However, successfully launching a new product across the region requires local infrastructure, expertise, and a deep knowledge of the complexities of these markets. This is where we come in.
We have mastered the complexities of operating in the different jurisdictions, languages, and cultures in the region; and we use our knowledge to maximize the potential for the commercial success of our partners’ products locally as well as regionally.
Our Value Proposition
The prospect of commercializing a product across The Middle East and African markets can be daunting. The idea of establishing a commercial organization and product from scratch in this environment is often overwhelming, and is sometimes simply written off.
Our value proposition bridges the gap between traditional go-it-alone and out-licensing strategies by providing a low risk shared-value approach. It could also be called a “go-it-alone – with us” strategy. We commercialize our partners’ products on their behalf. Our partnering models are tailored to fit our partners’ strategic goals, and allow them the option to recapture the asset and, if desired, the dedicated commercial organization we have built for them, at any time of the partnership.
Our value proposition bridges the gap between traditional go-it-alone and out-licensing strategies by providing a low risk shared-value approach. It could also be called a “go-it-alone – with us” strategy. We commercialize our partners’ products on their behalf. Our partnering models are tailored to fit our partners’ strategic goals, and allow them the option to recapture the asset and, if desired, the dedicated commercial organization we have built for them, at any time of the partnership.
Tailored Partnership Models
Our tailored partnership models for the commercialization of innovative specialty products, are made to fit our partners’ strategic goals.
For partners aiming to achieve a single market or regional footprint, we build and manage a dedicated go-to-market organization in the major Middle East & African markets. As for smaller assets that do not justify building a dedicated organization, we manage multiple, non-competing assets in aligned therapeutic areas, passing the synergies on to our partners in the form of improved economic terms.
Whatever market entry solution best fits their strategy, our partners work closely with a highly experienced and well connected team – from day one of the partnership.
For partners aiming to achieve a single market or regional footprint, we build and manage a dedicated go-to-market organization in the major Middle East & African markets. As for smaller assets that do not justify building a dedicated organization, we manage multiple, non-competing assets in aligned therapeutic areas, passing the synergies on to our partners in the form of improved economic terms.
Whatever market entry solution best fits their strategy, our partners work closely with a highly experienced and well connected team – from day one of the partnership.